Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-060147
Filing Date
2025-04-29
Accepted
2025-04-29 16:15:13
Documents
18
Period of Report
2025-06-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A apge-20250429.htm   iXBRL DEF 14A 1006514
2 GRAPHIC img64784460_0.jpg GRAPHIC 11611
3 GRAPHIC img64784460_1.jpg GRAPHIC 51893
4 GRAPHIC img64784460_2.jpg GRAPHIC 50395
5 GRAPHIC img64784460_3.jpg GRAPHIC 449374
6 GRAPHIC img64784460_4.jpg GRAPHIC 239365
  Complete submission text file 0000950170-25-060147.txt   3558069

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20250429.xsd EX-101.SCH 16048
20 EXTRACTED XBRL INSTANCE DOCUMENT apge-20250429_htm.xml XML 206770
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41740 | Film No.: 25887781
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)